^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiLi (adebrelimab)

    i
    Other names: SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316, SHR1316
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3d
    SHR-A2102-212: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tagrisso (osimertinib) • carboplatin • paclitaxel • SHR-A2102 • AiRuiLi (adebrelimab)
    13d
    A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    cisplatin • carboplatin • AiRuiLi (adebrelimab)
    13d
    MA-UC-II-007: Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (clinicaltrials.gov)
    P2, N=96, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Herceptin (trastuzumab) • carboplatin • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    14d
    Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=516, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • capecitabine • AiRuiLi (adebrelimab)
    14d
    Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based immunotherapy. (PubMed, Front Oncol)
    In this retrospective, single-center study, 35 ES-SCLC patients (median age: 72 years) treated with adebrelimab plus platinum-etoposide or platinum-irinotecan chemotherapy were analyzed. This suggests that CRP kinetics could serve as a practical, real-world biomarker for prognostication and early efficacy assessment in ES-SCLC. Prospective validation in larger cohorts is essential to confirm these findings.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    CRP (C-reactive protein)
    |
    etoposide IV • irinotecan • AiRuiLi (adebrelimab)
    14d
    Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (clinicaltrials.gov)
    P1/2, N=139, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • NKT2152
    16d
    Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=460, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tevimbra (tislelizumab-jsgr) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    16d
    Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Jinling Hospital, China | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    16d
    Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects (clinicaltrials.gov)
    P2, N=200, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • SHR-A2102 • AiRuiLi (adebrelimab)
    17d
    A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    gemcitabine • paclitaxel • AiRuiLi (adebrelimab) • SHR-7367
    17d
    A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P2 trial
    |
    Tagrisso (osimertinib) • carboplatin • paclitaxel • SHR-A2102 • AiRuiLi (adebrelimab)
    17d
    A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P3, N=720, Recruiting, Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • paclitaxel • AiRuiLi (adebrelimab)